<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03373695</url>
  </required_header>
  <id_info>
    <org_study_id>CL-VP-01</org_study_id>
    <nct_id>NCT03373695</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary In-stent Restenosis</brief_title>
  <official_title>A Multicenter, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of Dissolve™ Compared to SeQuent® Please in Treatment of Coronary In-stent Restenosis in Chinese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DK Medical Technology (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Core Medical (Beijing) Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>DK Medical Technology (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of treatment of coronary
      in-stent restenosis by Paclitaxel-eluting balloon catheter Dissolve™ versus SeQuent®Please,
      and the reference diameter of coronary artery stenosis is 2.5mm-4.0mm and the length ≤ 26mm.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-segment Late Lumen Loss</measure>
    <time_frame>From the end of procedure to 9 months after the procedure</time_frame>
    <description>In-segment late lumen loss is defined as the change in minimal lumen diameter (MLD) within the margins of the device and 5 mm proximal and 5 mm distal to the device from post-procedure to 9 months by angiography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device success rate of the interventional therapy</measure>
    <time_frame>From the start of index procedure to end of index procedure</time_frame>
    <description>Successful delivery and use of the assigned balloon at the intended target lesion and successful withdrawal of the delivery system with attainment of final residual stenosis of less than 30% and TIMI 3 blood flow by visual estimation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion success rate of the interventional therapy</measure>
    <time_frame>From the start of index procedure to end of index procedure</time_frame>
    <description>Attainment of final residual stenosis of target lesion less than 30% and TIMI 3 blood flow by visual estimation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success rate of the interventional therapy</measure>
    <time_frame>7 days after the procedure</time_frame>
    <description>Achievement of final residual stenosis of less than 30% by visual estimation with successful delivery and use of assigned balloon at the intended target lesion and successful withdrawal of the delivery system for the target lesion without the occurrence of cardiac death, target vessel Myocardial Infarction (MI) or repeat Target lesion revascularization (TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of restenosis in the target lesions</measure>
    <time_frame>9 months after the procedure</time_frame>
    <description>Restenosis is defined as stenosis &gt; 30% by angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLR rate</measure>
    <time_frame>9 months after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR) rate</measure>
    <time_frame>9 months after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure (TLF) rate</measure>
    <time_frame>9 months after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of major adverse cardiovascular events</measure>
    <time_frame>1 month, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years and 5 years after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of all adverse events and severe adverse events</measure>
    <time_frame>1 month, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years and 5 years after the procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Coronary In-stent Restenosis</condition>
  <arm_group>
    <arm_group_label>Dissolve™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SeQuent®Please</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dissolve™</intervention_name>
    <description>Dissolve™ are to be used in the trial</description>
    <arm_group_label>Dissolve™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SeQuent®Please</intervention_name>
    <description>SeQuent®Please are to be used in the trial</description>
    <arm_group_label>SeQuent®Please</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Related to the patients:

          1. Age ≥18 years old

          2. Patients who agree to accept the angiography follow-up visit at 9-month and follow up
             visits at 1-month, 6-month, 9-month, 1-year, 2-year, 3-year, 4-year and 5-year

          3. Patients with stable angina, unstable angina, old myocardial infarction or proven
             asymptomatic ischemia

          4. Patients who can receive any kind of coronary revascularization (including balloon
             angioplasty, stent implantation or coronary artery bypass grafting)

             Related to lesion:

          5. Restenosis after the first stent implant (including bare metal stents, stents with
             inert coating, and stents with active coating): Type Mehran I, Type II and Type III;
             the reference blood vessel diameter is 2.5 mm-4.0 mm, length ≤ 26mm

          6. Before surgery, stenosis diameter must be ≥ 70% or ≥ 50% and accompanied by ischemia

          7. The distance between other lesion requires interventional therapy and the target
             lesion must be &gt; 10mm

          8. One subject is allowed to have 2 target lesions at most, and 1 paclitaxel drug balloon
             for each lesion for dilation

          9. Residual stenosis must be ≤ 30% after pre-dilatation, and dissection must be ≤ NHLBI
             type B

        Exclusion Criteria:

        Related to patients

          1. Pregnant or lactating women, or women who plan to get pregnant within 12 months or
             refuse to take effective contraceptives

          2. Patients with cardiogenic shock

          3. The patients had cerebral stroke within 6 months before being included, or have a
             history of peptic ulcer or gastrointestinal bleeding, or the patients have a bleeding
             tendency according to the investigator. Patients who are forbidden to use
             anticoagulation agents or anti-platelet drugs, and unable to tolerate aspirin or
             clopidogrel. Patients who are not able to tolerate and comply with dual antiplatelet
             therapy for at least 3 months after operation

          4. Patients who have Myocardial Infarction with thrombus or coronary slow flow symptoms
             and require immediate intervention

          5. Patients who had ST-Elevation Myocardial Infarction within 1 week before being
             included

          6. Patients with severe congestive heart failure or NYHA grade IV heart failure

          7. Patients with moderate or severe valvular heart disease

          8. Patients who had heart transplantation

          9. Patients with renal insufficiency (eGFR &lt; 30mL/min)

         10. The patients have a life expectancy of less than 12 months, or it would be difficult
             to finish follow-ups within 12 months.

         11. The patients are participating in any other clinical trials before reaching the
             primary endpoints

         12. Patients who are unsuitable for the study according to the investigator due to other
             reasons

             Related to the Lesion:

         13. Patients with total occlusion at the target lesion

         14. Lesion which cannot be treated by percutaneous transluminal coronary angioplasty
             (PTCA) or percutaneous intervention (PCI)

         15. Reference vessel diameter &lt; 2.0mm

         16. Patients with multiple lesions (≥ 3) requiring percutaneous coronary intervention
             treatment in the same artery

         17. 3-vessel disease that all need to be intervened

         18. The diameter of the branch lesions in the target lesion ≥ 2.5mm

         19. LM lesions and Ostial lesion within 5mm to the root aorta

         20. Non-target lesion was not intervened successfully before target lesions being
             intervened

             Related to concomitant therapy:

         21. Patients cannot tolerate aspirin and/or clopidogrel and or tricagrelor, patients with
             the history of neutrocytopenia or thrombocytopenia, or patients with severe
             hypohepatia and prohibited to take clopidogrel

         22. Patients known allergic to paclitaxel

         23. Patients known allergic to contrast materials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shubin Qiao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shubin Qiao</last_name>
    <phone>86(010)88398866</phone>
    <email>qsbfw@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yujie Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fucheng Sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fuwai Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shubin Qiao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhujun Shen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weimin Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mao Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xuchen Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peng Qu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Daqing Oil Field</name>
      <address>
        <city>Daqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, Zhejiang University School of medicine</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guosheng Fu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chunguang Qiu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Hospital, Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qiutang Zeng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shaobin Jia</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>December 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

